Abstract

NEW CRYSTALLINE AND AMORPHOUS FORM OF A TRIAZOLO (4,5-D) PYRIMIDINE COMPOUND

A polymorph of the compound of formula (**I**), {1*S*-[1α, 2α, 3β (1*S**,2*R**),5β]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol and methods to prepare the polymorph. The compound cab be used as a medicament to antagonise the P_{2T} ($P2Y_{ADP}$ or $P2T_{AC}$) receptor and so as a medicament for treating or preventing arterial thrombotic complications in patients with coronary artery, cerebrovascular or peripheral vascular disease in a warm-blooded animal such as a human being.